Abstract
Introduction
Leukemia cutis (LC) refers to specific cutaneous eruptions resulting from various forms of leukemia. It was first described by Biesiadecki in 1876 as the infiltration of the skin by malignant hematopoietic cells. 1 It can be found in all forms of leukemia but is more common in myeloid leukemia.
2 Leukemia cutis can occur both in acute and chronic form of leukemia but frequently associated with acute type. The prevalence of LC is 10-15% in patients with acute myeloid leukemia (AML).
3
The clinical appearance of LC is variable, including macules, papules, plaques, nodules and ulcers. Lesions of LC may be localized or disseminated and can occur on any site of the skin. 4 In most cases, the presence of systemic disease precedes the appearance of skin lesions. 5 Rarely, cutaneous expression of the disease can occur before the evidence of leukemia in peripheral blood and bone marrow making it difficult to diagnose. 6 The diagnosis is made by clinical suspicion and confirmed by lesional skin biopsy, immunophenotyping and B or T cell receptor rearrangement studies. To confirm associated hematological malignancy, complete analysis of bone marrow aspirate and peripheral blood smear are required. Therapy of LC is mainly directed at the underlying hematological disease itself and the prognosis is related to the prognosis of the systemic disease. 7 We herein describe a patient with AML who presented with asymptomatic skin colored papules, nodules and plaques over face, scalp and trunk after four months of receiving single cycle chemotherapy.
Case report
A 32-year-old male known to have AML presented with multiple skin colored papules, nodules and plaques over face, scalp and trunk for 15 days (Fig 1) . Initially lesions appeared over forehead and right side of the cheek, then gradually spreads over face, scalp and trunk. Lesions were painless and non-pruritic. Other complaints include oral ulceration and difficulty in hearing for last four months. He was diagnosed as a case of AML four months prior to skin manifestations and received one cycle of chemotherapy. After one month of getting chemotherapy he developed invasive fungal sinusitis and was treated with systemic antifungal medication. He had history of significant weight loss (30 kg) over six months prior to admission. On physical examination, the patient was found severely anemic with below average body built. There was no associated lymphadenopathy. Examination of the integumentary system revealed multiple skin colored, smooth surfaced papules, nodules and infiltrated plaques distributed over scalp, face and trunk, fixed with skin and free from underlying structures, nontender and firm in consistency. A rounded atrophic scar with irregular margin was present on right cheek. Hyperpigmented depressed area was seen over the nasal bridge. Irregular whitish plaque was seen on the right side of the buccal mucosa and painless ulcerated area covered by whitish slough was found over hard palate near upper molar teeth. These lesions were non-tender. Nasal septal perforation was present. Alimentary system examination revealed hepatosplenomegaly. Nervous system examination revealed conductive type of deafness in right ear. On other systemic examination, no abnormalities were found.
Investigation reports showed Hb 7.3 gm/dL, ESR 140 mm in 1 st hour and WBC 12,500/cu mm (Neutrophil 82%). Chest radiography showed inhomogeneous patchy opacities in all zone of lung fields. USG of whole abdomen revealed mild hepatosplenomegaly. Histopathological examination of lesional skin biopsy showed absent granular layer and melanocyte incontinence in epidermis. The dermis revealed atypical mononuclear cells suggestive of leukemia cutis. Patient was advised for immunohistochemistry.
During hospital stay, three units of blood were transfused for correction of severe anemia. Unfortunately the patient denied to go for further investigations and was discharged with risk bond. Therefore, further treatment and follow-up was not possible.
Discussion
Involvement of skin with acute leukemia usually occurs in late stage. The commonest cutaneous lesions as reported by Su et al 8, 9 were of multiple papules, nodules (60%) or infiltrated plaques (26%), and varied from flesh-colored to red-brown or plum-colored. The site of predilection of LC differs among reports. While some studies reported no apparent predilection sites, others reported different predilection sites according to the type of leukemia.
4,10 ALL and CLL manifest mainly on the face or extremities. CML shows general distribution and AML is characterized by infiltration into oral mucosa.
11
The cutaneous infiltrate occurs predominantly in the dermis, with involvement of vessels, nerves and adnexal structures.
12 LC has a strong association with extramedullary disease, particularly the CNS. 13 The appearance of LC indicates a poor prognosis with around 88% mortality within a year of diagnosis. LC usually occurs concomitantly with or following bone marrow disease and may be the presenting sign of relapse of leukemia after chemotherapy.
4,14
Standard induction chemotherapy is less effective in AML patients with skin involvement and requires bone marrow, skin and extramedullary involvementdirected therapy.
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Conclusion
LC is often misdiagnosed or diagnosis may be delayed due to its rare occurrence and variable clinical presentation. As non-leukemic cutaneous manifestations of leukemia are much more common, the possibility of LC should always be kept in mind and ruled out by relevant investigations. Although, histopathological findings are useful to reach the correct diagnosis, various other parameters including electron microscopy, cytochemistry and immunophenotypic studies are mostly required for exact characterization of the malignant cells. Early diagnosis and initiation of appropriate treatment is necessary as LC patients have a poor prognosis with an inevitably progressive course.
